DMAC - DiaMedica Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7000
-0.3000 (-10.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.0000
Open2.8800
Bid0.5000 x 1000
Ask3.6800 x 1300
Day's Range2.6900 - 2.9500
52 Week Range2.4600 - 13.7740
Volume20,845
Avg. Volume50,382
Market Cap32.284M
Beta (3Y Monthly)1.23
PE Ratio (TTM)N/A
EPS (TTM)-0.9160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • ACCESSWIRE5 days ago

    DiaMedica Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 14, 2019 / DiaMedica Therapeutics, Inc. (NASDAQ: DMAC ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 14, 2019 at 8:00 ...

  • GlobeNewswire6 days ago

    DiaMedica Therapeutics Announces First Quarter 2019 Financial Results and Provides Business Update

    Phase Ib study of DM199 in Chronic Kidney Disease nearing full enrollmentCompletion of new cGMP manufacturing run of DM199Conference call with management tomorrow, May 14, 2019.

  • GlobeNewswire13 days ago

    DiaMedica Therapeutics to Report First Quarter 2019 Financials and Provide an Update on Development Programs on May 14, 2019

    MINNEAPOLIS, May 06, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its first quarter 2019 financial results will be released after market close on.

  • GlobeNewswire19 days ago

    DiaMedica Therapeutics to Present at CKD3 Kidney Summit Meeting

    DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biotechnology company, today announced that Dr Harry Alcorn, its Chief Medical Officer will be presenting “CKD New Therapeutic Development: DM199 for Chronic Kidney Disease” at the Chronic Kidney Disease Drug Development (“CKD3”) summit in Boston on Tuesday May 7, 2019, at 1:30 Eastern Time. CKD3 is a uniquely focused conference that unites key opinion leaders to identify and discuss critical factors in determining the success of current chronic kidney disease (“CKD”) pipelines and evaluate new treatments that have the potential to significantly impact the standard of care for this serious unmet medical need. Leading experts from innovative biotechnology and pharmaceutical companies, academia and key service providers come together at the CKD3 summit to present comprehensive insight into the cutting-edge progress of CKD drug development research.

  • GlobeNewswire2 months ago

    DiaMedica Therapeutics Announces 2018 Financial Results and Provides Corporate Update

    Dosed first patients in Phase Ib study of DM199 in Chronic Kidney Disease patients under an IND accepted by the FDA in 2018; Plan to initiate Phase II studies in 2H 2019Acute.

  • GlobeNewswire2 months ago

    DiaMedica Therapeutics Announces Date for the Release of Full Year 2018 Results and Conference Call

    MINNEAPOLIS, March 18, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its 2018 financial results will be released after market close on Tuesday, March.

  • GlobeNewswire2 months ago

    DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019

    MINNEAPOLIS, March 12, 2019 -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The.

  • GlobeNewswire3 months ago

    DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (DMAC), a clinical-stage biotechnology company, today announced that it has initiated dosing patients with chronic kidney disease (“CKD”) in a Phase Ib clinical study evaluating DM199.  The Phase 1b study, conducted in the US, is a multi-center, open label clinical trial to evaluate the safety, tolerability and pharmacokinetics of three dose levels of DM199 in 32 patients with moderate and severe CKD. “This study will assist in determining dose levels required to restore normal KLK1 protein levels in patients with CKD and provide additional insights about the specific CKD patient populations that may benefit most from DM199 treatment and to guide the design of upcoming Phase II studies,” said Dr. Harry Alcorn, Chief Medical Officer at DiaMedica Therapeutics.

  • GlobeNewswire4 months ago

    DiaMedica Therapeutics Announces Publication of a Paper, “Human Tissue Kallikrein in the Treatment of Acute Ischemic Stroke,” in the Journal Therapeutic Advances in Neurological Disorders

    MINNEAPOLIS, Jan. 22, 2019 -- DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announces the publication of a paper titled  “Human Tissue Kallikrein In The Treatment Of Acute Ischemic.

  • OTC Markets Group Announces Quarterly Index Performance and Rebalancing
    PR Newswire4 months ago

    OTC Markets Group Announces Quarterly Index Performance and Rebalancing

    NEW YORK , Jan. 16, 2018 /PRNewswire/ --   OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the fourth quarter 2018 performance ...

  • Benzinga4 months ago

    The Daily Biotech Pulse: Cancer Genetics Prices Offering, DiaMedica Delists From Canadian Exchange, Medigus CEO Quits

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks struck 52-week highs Jan. 9:  China SXT Pharmaceuticals Inc (NASDAQ: SXTC ...

  • GlobeNewswire4 months ago

    DiaMedica Therapeutics Announces Voluntary Delisting from TSX Venture Exchange

    DiaMedica Therapeutics Inc. (DMAC) (DMA.V), a clinical stage biopharmaceutical company, announced today that it has applied to voluntarily delist its voting common shares from the TSX Venture Exchange. The Company’s common shares are expected to be delisted from the TSX-V at the close of business on January 18, 2019, being approximately 10 days from today's date.  DiaMedica’s shares will continue to be listed for trading on The Nasdaq Capital Market (“Nasdaq”) under the trading symbol “DMAC.”  The Company believes that the continued listing of its common shares on the Nasdaq will provide its Canadian shareholders with a sufficiently liquid market and further, that the financial and administrative costs associated with maintaining a dual listing are not justified.

  • GlobeNewswire4 months ago

    UPDATE - DiaMedica Announces FDA Clearance of IND Application To Study DM199 in Patients with Chronic Kidney Disease

    DiaMedica Therapeutics Inc. (“DiaMedica”) (DMAC) (DMA.V) announced today that the U.S. Food and Drug Administration ("FDA") has accepted DiaMedica’s Investigational New Drug application ("IND") for the initiation of a Phase Ib clinical trial of DM199 in patients with moderate or severe Chronic Kidney Disease (“CKD”) caused by Type I or Type II diabetes. The multi-site clinical study will enroll 32 subjects to evaluate DM199 safety, tolerability and drug levels (pharmacokinetics) in this specific population. The results from this Phase Ib study will assist DiaMedica in the design of upcoming Phase II studies in patients suffering from rare diseases and CKD.

  • Benzinga5 months ago

    IPO Outlook For The Week: Proteins, Fashion And Finance

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Mogu Inc. (MOGU) will issue 4.75 million shares between $14 and $16 Wednesday on the New York Stock Exchange. The Chinese ...